Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today preliminary 48 week clinical data obtained from its Phase III psoriasis and extension trials for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will announce preliminary 48 week clinical trial data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00 a.m. MST. Management will provide an overview of the preliminary 48 week Phase III data following the release ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company enrolled its first patient in a North American Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247, on January 4, 2006. The trial will be performed at thirty-four centers across North America , including twenty-nine centers in the United States and ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today nine month interim safety and efficacy data obtained from its 24 week Phase III psoriasis trial and 12 week extension for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an ...
Edmonton, Canada, November 16 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA), a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics, announced today that effective immediately, Joseph Koziak, who served as Executive Vice President is no longer an officer of the company. About Isotechnika Isotechnika Inc. is an international biopharmaceutical ...
Edmonton, Canada, November 7 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A summary of the results is as follows: - All primary and secondary efficacy endpoints were achieved at 24 weeks - Efficacy endpoints were ...
Edmonton, Canada, November 4 (ots/PRNewswire) - - ATTN: Business/Assignment Editors: EDMONTON, Canada, November 4 /PRNewswire/ -- Isotechnika Inc. will announce the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247 on Monday, November 7th at 7:00 a.m. EST/5:00a.m. MST. Management will ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. ("Isotechnika") and Atrium Medical Corporation ("Atrium") jointly announced today the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today the unblinded 12 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A Summary of the results is as follows: - The study met all primary and secondary efficacy endpoints determined at 12 weeks - Efficacy endpoints were achieved with minimal side effects - No clinically ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the participation level in its Canadian Phase III psoriasis extension trial for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to discontinue ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis (SPIRIT) trial commenced on December 2, 2004 and includes a total of 453 patients with ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. The planned randomized, open-label trial will include approximately 332 de novo (newly ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company will web cast its Annual General Meeting in Toronto on Tuesday, May 10, 2005 at 10:00 a.m. EDT. The web cast will include corporate and scientific updates. The web cast will be chaired by Dr. Robert Foster, Chairman and CEO; with Dr. Randall Yatscoff, President and COO presenting the scientific update. Interested parties can ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. This randomized, open-label trial will include approximately 332 de novo (newly transplanted) kidney patients. Patients ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to show promising results. The Canadian Phase III Psoriasis trial (SPIRIT) which commenced on December 2, 2004, includes a total of 453 patients with stable moderate to severe plaque psoriasis. The trial is currently being conducted in 32 sites and ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Company has been issued U.S. Patent No. 6,878,550 for its diagnostic breath test kit, Diatest(R). The patent entitled "13C Glucose Breath Test for the Diagnosis of Diabetic Indications and Monitoring Glycemic Control" is the fifth U.S. Patent issued for this technology. ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the original target of 400 subjects for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247 has been reached. Due to the enthusiasm of our investigators and the willingness of patients to participate in the trial, the Company will allow approximately 80 ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has completed recruitment for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247. Of the 400 subjects enrolled in the trial, 207 subjects have commenced treatment. The Company received a "No Objection Letter" from Health Canada on December 1, 2004 and commenced the trial on December 2, 2004. ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing has begun. The Phase III trial will be performed over a twenty-four week period at thirty-three centers across Canada involving a ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase III trial for its lead immunosuppressive drug candidate, ISA247. The trial will be performed over a twenty-four week period at thirty- ...
Edmonton, Canada, November 3 (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has successfully completed the multiple ascending dose study for its lead immunosuppressive drug, ISA247. The multiple ascending dose (MAD) study for ISA247 that commenced on June 3, 2004 involved a total of 43 subjects. The study, conducted by SFBC Anapharm in ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today the appointment of Patrice R. Debregeas to its board of directors. As Chairman, CEO and President of Ethypharm S.A, the leading drug delivery company in Europe, Mr. Debregeas brings extensive international experience in the pharmaceutical ...
Edmonton, Alberta, Canada (ots/PRNewswire) - Isotechnika Inc. announced today they have received the interim results of the QTc trial for its lead immunosuppressive drug, ISA247 from eResearch Technology Inc. The study, conducted by Pracs in Fargo, North Dakota was designed as a double blind, parallel group, placebo and moxifloxacin controlled, randomized, single dose QTc study of trans-ISA247 in healthy volunteers. In ...
EDMONTON, Canada, July 7 (ots/PRNewswire) - Isotechnika Inc. today announced that the Company has received permission from the Food and Drug Administration of the United States for the commencement of a Phase Ib human clinical trial for TAFA-93. TAFA-93 is a novel prodrug of the mTOR inhibitor rapamycin designed to reduce the unfavourable pharmacokinetics ...
EDMONTON, Canada, July 6 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today the completion of the single ascending dose trial for the Company's lead immunosuppressive drug candidate, ISA247. The SAD trial was conducted in healthy volunteers using the trans-ISA247 formulation to assess the appropriate dosage of the enhanced composition of the drug. The data confirms that the trans formulation of ...